Lynn Dressler, DrPH
Lynn Dressler is the director of personalized medicine of the Fullerton Genetics Center at Mission Health in Asheville, NC. She joined the center in February 2013, to develop and direct the personalized medicine and pharmacogenomics program.
Formerly a faculty member in the Schools of Medicine and Pharmacy at the University of North Carolina at Chapel Hill, and a founding member of UNC Center for Pharmacogenomics and Individualized Therapy, Dressler’s thirty-year career spans translational laboratory research in cancer, health policy research, and the ELSI and policy implications of genomic medicine. Dressler holds a master’s in experimental pathology and a doctorate in health policy, and she completed a fellowship in ELSI research.
At UNC, her laboratory conducted the research study that directly led to the FDA approval of the HER2 FISH assay (PathVYsion™), one of the first pharmacogenomic tests in solid tumors. In North Carolina, nearly ten years prior to GINA, Dressler worked with the NC General Assembly to draft legislation that was passed into law to prohibit discrimination by employers and health insurance providers on the basis of an individual’s genetic information, paving the way for cancer genetic studies to proceed in that state while providing some protection for cancer patients.
At the national level, working closely with NIH/NCI/NHGRI, Dressler has served in many leadership roles (external adviser to TCGA study, NCI caHUB ethics working group, eMERGE Return of Results and Data Sharing Working Groups). Dressler currently serves as a member of the Clinical Pharmacogenomics Implementation Committee, the Ethics and Policy Working Group of the NHGRI/NCI International Cancer Genome Consortium, and a guest member of the Institute of Medicine’s Roundtable on Translating Genomic Findings to Improve Health.